Purpose of review
Accelerated schedules for administering subcutaneous aeroallergen immunotherapy have the potential to provide convenience, reduce the cost, and improve compliance over conventional (weekly) schedules. In this review, we describe studies of cluster and rush immunotherapy (RIT), the risk of systemic allergic reactions (SARs) for various schedules, and methods to reduce that risk.
Cluster schedules are associated with a slightly increased risk of a SAR that can be reduced by taking an H1 antihistamine on the day of injections. The risk of a SAR can also be reduced with depo extracts, fewer injections per cluster, and administration of fewer than 3 clusters per week. RIT is associated with a 27 to 38% risk of a SAR that can be reduced with administration of corticosteroids, an H1 and H2 antihistamine and possibly a leukotriene blocker for 3 days prior to the procedure and by stopping at a lower dose. Reactions tend to occur 1–2 h after the last injection on the day of RIT, and there is an increased risk of a reaction if subsequent weekly doses are missed.
Accelerated immunotherapy schedules can offer benefits over weekly schedules; however, the increased risk of a SAR needs to be considered when deciding to recommend such a schedule.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
• Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55 A practice parameter that describes guidelines for administering aeroallergen immunotherapy.
Cox LS, Sanchez-Borges M, Lockey RF. World Allergy Organization Systemic Allergic Reaction Grading System: is a modification needed? J Allergy Clin Immunol Pract. 2017;5(1):58–62 e5.
Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468–75.
•• Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006;97(2):126–37 quiz 37–40, 202. A comprehensive review of accelerated immunotherapy schedules as of 2006.
Tabar AI, Echechipia S, Garcia BE, Olaguibel JM, Lizaso MT, Gomez B, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116(1):109–18.
Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol. 1996;76(2):175–80.
Portnoy J, King K, Kanarek H, Horner S. Incidence of systemic reactions during rush immunotherapy. Ann Allergy. 1992;68(6):493–8.
Cox L. Advantages and disadvantages of accelerated immunotherapy schedules. J Allergy Clin Immunol. 2008;122(2):432–4.
Xie W, Zhang H, Chen J, Wang Y. Clinical efficacy and safety of rush immunotherapy in patients with allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;50(8):641–5.
Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol. 1993;91(3):734–7.
•• Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008–2013). Ann Allergy Asthma Immunol. 2016;116(4):354–9 e2 A recent surveillance study of SRs in patients receiving subcutaneous immunotherapy to aeroallergens.
Kohno Y, Minoguchi K, Oda N, Yokoe T, Yamashita N, Sakane T, et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol. 1998;102(6 Pt 1):927–34.
Van Metre TE Jr, Adkinson NF Jr, Amodio FJ, Kagey-Sobotka A, Lichtenstein LM, Mardiney MR Jr, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol. 1982;69(2):181–93.
Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008–2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract. 2014;2(2):161–7.
Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 1996;97(6):1207–13.
Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125(2):383–9.
Parmiani S, Fernandez Tavora L, Moreno C, Guardia P, Rico P. Clustered schedules in allergen-specific immunotherapy. Allergol Immunopathol (Madr). 2002;30(5):283–91.
Winslow AW, Turbyville JC, Sublett JW, Sublett JL, Pollard SJ. Comparison of systemic reactions in rush, cluster, and standard-build aeroallergen immunotherapy. Ann Allergy Asthma Immunol. 2016;117(5):542–5.
Copenhaver CC, Parker A, Patch S. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice. Ann Allergy Asthma Immunol. 2011;107(5):441–7.
Cox LS. Shooting for a faster approach to the immunotherapy target: will cluster become conventional? Ann Allergy Asthma Immunol. 2009;102(3):177–8.
Bousquet J, Hejjaoui A, Skassa-Brociek W, Guerin B, Maasch HJ, Dhivert H, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol. 1987;80(4):591–8.
Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol. 1989;83(4):797–802.
Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 1990;85(2):473–9.
Harvey SM, Laurie S, Hilton K, Khan DA. Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol. 2004;92(4):414–9.
Smits WL, Giese JK, Letz KL, Inglefield JT, Schlie AR. Safety of rush immunotherapy using a modified schedule: a cumulative experience of 893 patients receiving multiple aeroallergens. Allergy Asthma Proc. 2007;28(3):305–12.
Temino VM, Wu P, Konig J, Fahrenholz JM. Safety of multiple aeroallergen rush immunotherapy using a modified schedule. Allergy Asthma Proc. 2013;34(3):255–60.
• Sastre J, Vallejo L, Hernandez E, Fernandez-Nieto M, Nieto PR. A novel mode for delivering immunotherapy using an infusion pump. Ann Allergy Asthma Immunol. 2011;107(5):459–60.A novel mode for delivering immunotherapy using an infusion pump.
Uriarte Obando SA, Sastre Dominguez J. Safety of rush subcutaneous immunotherapy administered in real life using an infusion pump. Ann Allergy Asthma Immunol. 2015;115(6):527–9.
•• Fajt ML, Rosenberg SL, Yecies E, Traister RS, Petrov AA. A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol. Allergy Asthma Proc. 2017;38(4):309–16 A recent and extensive review of experience with rush immunotherapy.
Fernandez Tavora L. Aqueous extracts and cluster schedule: a good approach for immunotherapy buildup phase. Allergy. 1995;50(26):0592.
Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000;30(10):1423–9.
Quiralte J, Justicia JL, Cardona V, Davila I, Moreno E, Ruiz B, et al. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy. Immunotherapy. 2013;5(12):1295–303.
Tabar AI, Muro MD, Garcia BE, Alvarez MJ, Acero S, Rico P, et al. Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy. J Investig Allergol Clin Immunol. 1999;9(3):155–64.
Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;107(1):87–93.
Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects. Allergy. 2000;55(9):827–35.
Cardona R, Lopez E, Beltran J, Sanchez J. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study. Allergol Immunopathol (Madr). 2014;42(2):90–5.
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134–40.
Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007;120(3):688–95.
• Morais-Almeida M, Arede C, Sampaio G, Borrego LM. Ultrarush schedule of subcutaneous immunotherapy with modified allergen extracts is safe in pediatric age. Asia Pac Allergy. 2016;6(1):35–42 Recent study of Ultrarush using a 1-day protocol with allergoids.
Pfaar O, van Twuijver E, Hecker H, Boot JD, van Ree R, Klimek L. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation. Int Arch Allergy Immunol. 2013;160(4):420–4.
• Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy. 1994;73(5):409–18 Initial study showing that premedication reduces the risk of a SR in 1-day RIT.
Stevens WJ, Verhelst JA, van den Bogaert W, Bridts CH. Clinical and biological evaluation of semi-rush and ordinary immunotherapy schemes in type I allergic respiratory diseases. Allergy. 1985;40(6):447–52.
Conflict of Interest
Jessica Van Mason declares that she has no conflict of interest.
Jay M. Portnoy declares that he has no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
• Cluster schedules are associated with a slightly increased risk of a SAR that can be reduced by taking an H1 antihistamine on the day of injections
• RIT is associated with a 27 to 38% risk of a SAR
• The risk of a SAR can be reduced with administration of corticosteroids, an H1 and H2 antihistamine and possibly a leukotriene blocker for 3 days prior to RIT
• Reactions during RIT tend to occur 1–2 h after the last injection so patients should be observed for that amount of time
This article is part of the Topical Collection on Specific Immunotherapy
About this article
Cite this article
Van Mason, J., Portnoy, J.M. Accelerated Immunotherapy: Why Are We Going So Slow?. Curr Treat Options Allergy 6, 396–409 (2019). https://doi.org/10.1007/s40521-019-00212-3
- Rush immunotherapy
- Cluster immunotherapy